Cargando…

Data silos are undermining drug development and failing rare disease patients

Data silos are proliferating while research and development activity explode following genetic and immunological advances for many clinically described disorders with previously unknown etiologies. The latter event has inspired optimism in the patient, clinical, and research communities that disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Denton, Nathan, Molloy, Monique, Charleston, Samantha, Lipset, Craig, Hirsch, Jonathan, Mulberg, Andrew E., Howard, Paul, Marsh, Eric D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Position Statement
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025897/ https://www.ncbi.nlm.nih.gov/pubmed/33827602 http://dx.doi.org/10.1186/s13023-021-01806-4

Ejemplares similares

Sharing is caring: a call for a new era of rare disease research and development
por: Denton, Nathan, et al.
Publicado: (2022)

Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders
por: Mulberg, Andrew E., et al.
Publicado: (2019)

Correction to: Sharing is caring: a call for a new era of rare disease research and development
por: Denton, Nathan, et al.
Publicado: (2023)

Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases
por: Douglas, Conor M. W., et al.
Publicado: (2022)

Epidemiology of rare diseases in Brazil: protocol of the Brazilian Rare Diseases Network (RARAS-BRDN)
por: Félix, Têmis Maria, et al.
Publicado: (2022)

A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs
por: Cui, Yazhou, et al.
Publicado: (2015)

Compounded medication for patients with rare diseases
por: Dooms, Marc, et al.
Publicado: (2018)

Position statement on access to care in rare liver diseases: advancements of the European reference network (ERN) RARE-LIVER
por: Bernts, Lucas H. P., et al.
Publicado: (2019)

Rare diseases in Tanzania: a National Call for Action to address policy and urgent needs of individuals with rare diseases
por: Kaywanga, Frida, et al.
Publicado: (2022)

From scientific discovery to treatments for rare diseases – the view from the National Center for Advancing Translational Sciences – Office of Rare Diseases Research
por: Kaufmann, Petra, et al.
Publicado: (2018)

eHealth for patients with rare diseases: the eHealth Working Group of the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN)
por: Paglialonga, Alessia, et al.
Publicado: (2021)

Rare disease education in Europe and beyond: time to act
por: Tumiene, Birute, et al.
Publicado: (2022)

Pharmacists are initiators in palliative care for patients with rare diseases
por: Dooms, M.
Publicado: (2023)

European Reference networks for rare diseases: what is the conceptual framework?
por: Héon-Klin, Véronique
Publicado: (2017)

A patient advocating for transparent science in rare disease research
por: Yang, Richard Rui
Publicado: (2023)

Increasing African genomic data generation and sharing to resolve rare and undiagnosed diseases in Africa: a call-to-action by the H3Africa rare diseases working group
por: Lumaka, Aimé, et al.
Publicado: (2022)

Pharmaceutical pricing, cost containment and new treatments for rare diseases in children
por: Stella, Peter, et al.
Publicado: (2014)

Rare diseases in Chile: challenges and recommendations in universal health coverage context
por: Encina, Gonzalo, et al.
Publicado: (2019)

Clinical management guidelines for Friedreich ataxia: best practice in rare diseases
por: Corben, Louise A., et al.
Publicado: (2022)

European expert network on rare communicable diseases and other rare diseases linked to mobility and globalisation focused on health care provision (EURaDMoG): a feasibility study
por: Requena-Méndez, Ana, et al.
Publicado: (2020)

The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference Networks
por: Evangelista, Teresinha, et al.
Publicado: (2016)

TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases
por: Annemans, Lieven, et al.
Publicado: (2020)

The need for widely available genomic testing in rare eye diseases: an ERN-EYE position statement
por: Black, Graeme C., et al.
Publicado: (2021)

European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT)
por: Shovlin, Claire L., et al.
Publicado: (2018)

RD-RAP: beyond rare disease patient registries, devising a comprehensive data and analytic framework
por: Bellgard, Matthew I., et al.
Publicado: (2019)

Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)
por: Annemans, Lieven, et al.
Publicado: (2017)

Providing high-quality care remotely to patients with rare bone diseases during COVID-19 pandemic
por: Brizola, E., et al.
Publicado: (2020)

Integrating rare disease management in public health programs in India: exploring the potential of National Health Mission
por: Choudhury, Mohua Chakraborty, et al.
Publicado: (2022)

Clinical development innovation in rare diseases: lessons learned and best practices from the DevelopAKUre consortium
por: Rudebeck, Mattias, et al.
Publicado: (2021)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Recommendations from the IRDiRC Working Group on methodologies to assess the impact of diagnoses and therapies on rare disease patients
por: Zanello, Galliano, et al.
Publicado: (2022)

Towards the international interoperability of clinical research networks for rare diseases: recommendations from the IRDiRC Task Force
por: Nabbout, Rima, et al.
Publicado: (2023)

Measuring what matters to rare disease patients – reflections on the work by the IRDiRC taskforce on patient-centered outcome measures
por: Morel, Thomas, et al.
Publicado: (2017)

European reference network for rare vascular diseases (VASCERN) consensus statement for the screening and management of patients with pathogenic ACTA2 variants
por: van de Laar, Ingrid M. B. H., et al.
Publicado: (2019)

Critical appraisal of arguments for the delayed-start design proposed as alternative to the parallel-group randomized clinical trial design in the field of rare disease
por: Spineli, Loukia M., et al.
Publicado: (2017)

European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT)
por: Eker, Omer F., et al.
Publicado: (2020)

Expansion of India’s national child healthcare programme, Rashtriya Bal Swasthya Karyakram (RBSK), for rare disease management : a health policy perspective
por: Chaube, Pragya, et al.
Publicado: (2023)

The German National Action League for people with rare diseases: translating the three tiers center system into active co-operation, a one center experience
por: Plöckinger, U., et al.
Publicado: (2019)

The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases – recommendations of the IRDiRC Data Mining and Repurposing Task Force
por: Southall, Noel T, et al.
Publicado: (2019)

Registries for orphan drugs: generating evidence or marketing tools?
por: Hollak, Carla E. M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jb1ltqd8mtc8u4c9cplcd0g73u